Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

Regular price $7,495.00 Sale

Published on Mar 12, 2013 - 183 pages

The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera's launch in Europe. Genzyme have taken advantage of this delay with Lemtrada's (alemtuzumab) and Aubagio's (teriflunomide) EU approval. The arrival of these drugs is expected to transform multiple sclerosis treatment and be a catalyst for unprecedented market growth.

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.3 billion in 2012 to $21.5 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers

For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative diabetes market forecast look no further than FirstWord's Therapy Trends: Multiple Sclerosis. This comprehensive FirstWord research is available in two comprehensive modules:
  • The KOL Insight: Multiple Sclerosis module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
  • The Consensus Outlook: Multiple Sclerosis data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections
KOL Insight

Therapy Trends KOL Insight: Multiple Sclerosis analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:
  • KOL Insight Report - an in-depth analytical report on diabetes treatment trends
  • Full report updates - issued to you after each and every significant diabetes market event
  • Event Bulletins - the latest KOL views in response to each event
Key Report Features and Benefits
  • Critical insights on products and market developments from leading US and European clinicians
  • Critical insights on products and market developments from leading US, European and Australian clinicians
  • Assessment of current leading multiple sclerosis products
  • Analysis of late-stage pipeline multiple sclerosis therapies
  • Competitive evaluation of leading players
  • Current thinking and trends in the treatment of multiple sclerosis
  • Predicted KOL treatment trends and market leaders
  • Ongoing FirstWord clinical and market updates
Expert Opinion for Real World Insights

The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in multiple sclerosis in the US, Europe and Australia. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.

KOL Panel
  • David Hafler, Chief and Chair of Neurology at Yale-New Haven Hospital and Yale School of Medicine, New Haven, Connecticut, US
  • Professor Douglas Jeffery, MD, PhD, Associate Professor of Neurology, the Department of Neurology, The Multiple Sclerosis and Movement Disorders Centre at Advance Neurology at Cornerstone Health Care Winston-Salem, North Carolina, US
  • Professor Paul O'Connor, Professor, Division of Neurology, University of Toronto, Toronto, Canada
  • Professor Lawrence Steinman, Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics, Stanford University School of Medicine, California, US
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at the Ottawa Hospital Research Institute, Ottawa, Canada (requested anonymous)
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at the Mount Sinai School of Medicine, New York, US (requested anonymous)
  • Dr Mike Bogglid, Staff Specialist Neurologist, Townsville Hospital, University of Queensland, Australia
  • Dr Patrick Vermersch, Department of Neurology, University of Lille North of France, Hopital Roger Salengro, Lille, France
  • Dr Heinz Wiendl, Department of Neurology, Neuroimmunology and Neuro-Oncology, University of Muenster, Muenster, Germany
  • Dr Martin Wilson. Consultant Neurologist, Walton Centre for Neurology and Neurosurgery NHS Trust, Liverpool, UK
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at Centre Neurologique et de Readaptation Fonctionnelle, Fraiture-en-Condroz, Belgium (requested anonymous)
  • Professor and Medical Neurologist, MD, and expert in multiple sclerosis at Heinrich-Heine University, Dusseldorf, Germany (requested anonymous)
Key Quotes from the Report

"I think alemtuzumab is an excellent drug. It's very, very efficacious, and surprisingly well tolerated, considering its potency. They do need some blood monitoring each month but it's actually pretty easy to give and to monitor and certainly very effective." Dr Martin Wilson (Europe)

"Using Lemtrada is different from the other options we have available. It is a real investment in the patient's time. You enter into a contract over five years at least with monthly monitoring. That is something that a lot of patients cannot really foresee when they start such therapies. They need to have a certain insight into the disease and its nature. This is a difference between, let's say, a drug that you rather easily start on and get off, like Tecfidera versus Lemtrada, that is something you start and you don't get off ever." Dr Heinz Wiendl (EU)

"I think teriflunomide is moderately effective. It seems that there are no major severe risks. I would put it in the efficacy range of the current injectables, I don't think it offers an advantage over the currently available first-line drugs, but of course, as a tablet it's more convenient and would hold the promise of increasing adherence" European Key Opinion Leader

KOL Insights -- Key Topics
  • Current multiple sclerosis marketplace
  • Current treatment landscape
  • Reimbursement of key multiple sclerosis brands
  • Unmet needs
  • Current therapies
  • Symptomatic treatment
  • Pipeline therapies
  • Future developments in multiple sclerosis
Consensus Outlook